Birchview Capital »

Adagene shares owned by Birchview Capital

Quarter-by-quarter ownership of Adagene (ADAG) shares owned by Birchview Capital from 13F filings

Historical chart of Birchview Capital investment in Adagene

Tip: Access up to 7 years of quarterly data

All positions including Adagene held by Birchview Capital consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Adagene by Birchview Capital

Quarter filed Position value Share count Share price at filing
2026-06-30 $1.0M 240k 4.20

More positions owned by Birchview Capital

Kla Corporation Com New (KLAC)
Bristol Myers Squibb (BMY)
Lam Research Corporation Com New (LRCX)
Solid Biosciences Com New (SLDB)
Intellia Therapeutics (NTLA)
Biodesix
Stoke Therapeutics (STOK)
Encana Corporation (OVV)
Nektar Therapeutics (NKTR)
Corcept Therapeutics Incorporated (CORT)
Neurocrine Biosciences (NBIX)
Prothena Corp SHS (PRTA)
ACADIA Pharmaceuticals (ACAD)
Protagonist Therapeutics (PTGX)
Compass Therapeutics (CMPX)

View all positions for Birchview Capital

Top funds holding Adagene

Jupiter Topco
Deerfield Management Company
Siren
Ameriprise Financial
Sc China Holding
Squadron Capital Management
Dauntless Investment Group
Citadel Advisors
Exome Asset Management
Birchview Capital
Moneta Group Investment Advisors
Pathstone Holdings
Mill Creek Capital Advisors
Renaissance Technologies
UBS Group

View all funds holding Adagene